Our Story

Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
10.16.2019

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

view full story

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
10.08.2019

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

view full story

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology
09.28.2019

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

view full story

FORMA Therapeutics Announces New Executive Leadership To Execute Next Phase Of Growth For Company
09.24.2019

FORMA Therapeutics Announces New Executive Leadership To Execute Next Phase Of Growth For Company

view full story

Kymera Therapeutics is Named one of FierceBiotech’s “Fierce 15” Companies of 2019
09.23.2019

Kymera Therapeutics is Named one of FierceBiotech’s “Fierce 15” Companies of 2019

view full story

Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team
09.19.2019

Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team

view full story

FORMA Therapeutics Announces Data For IDH1m Inhibitor Olutasidenib In Glioma To Be Presented At The 2019 Society For NeuroOncology Annual Meeting
09.11.2019

FORMA Therapeutics Announces Data For IDH1m Inhibitor Olutasidenib In Glioma To Be Presented At The 2019 Society For NeuroOncology Annual Meeting

view full story

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
09.03.2019

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium

view full story

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
08.01.2019

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study

view full story

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
07.24.2019

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency

view full story

Kymera Therapeutics Announces Leadership Transitions
07.15.2019

Kymera Therapeutics Announces Leadership Transitions

view full story

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology
07.09.2019

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

view full story

Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy
06.27.2019

Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

view full story

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
06.24.2019

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach

view full story

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
06.03.2019

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency

view full story

Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019
05.24.2019

Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019

view full story

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases
05.15.2019

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

view full story

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
05.14.2019

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study

view full story

Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
05.08.2019

Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists

view full story

Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
04.07.2019

Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

view full story

Forma Therapeutics Announces Frank D. Lee As Chief Executive Officer
03.21.2019

Forma Therapeutics Announces Frank D. Lee As Chief Executive Officer

view full story

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
03.15.2019

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

view full story

Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
02.04.2019

Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388

view full story

Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
01.16.2019

Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

view full story

Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
01.09.2019

Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia

view full story

Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic
12.18.2018

Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic

view full story

Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences
12.14.2018

Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences

view full story

Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
12.13.2018

Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943

view full story

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
12.11.2018

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency

view full story

Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
11.27.2018

Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease

view full story

Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
11.27.2018

Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers

view full story

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
11.13.2018

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

view full story

Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200
11.06.2018

Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200

view full story

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model
11.05.2018

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

view full story

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
11.01.2018

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

view full story

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
10.22.2018

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress

view full story

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
10.17.2018

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

view full story

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
10.12.2018

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

view full story

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study
10.05.2018

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study

view full story

Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer
10.04.2018

Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer

view full story